Pharmafile Logo

Competition from within

August 25, 2015 | emerging markets 

Published in eyeforpharma July 29 by Rachel Howard

To what extent can Big Pharma expect to face an increasing challenge from globalizing pharmaceutical companies based in emerging markets?

If we take a look at the top 50 pharmaceutical companies of 2013, they are mainly headquartered in North America (18), the EU (18) or Japan (9). Teva (Israel), CSL (Australia) and Aspen (South Africa) are notable exceptions, with the Indian generic giants Sun and Ranbaxy – which have since merged – the only representation from the ‘BRIC’ markets (Brazil, Russia, India and China). In ten years’ time, will more ‘home-grown’ emerging market companies feature on this list?

In this article, I will explore and compare the directions the domestic pharmaceutical industries of South Korea, China and Brazil have taken in recent years, and consider what threat, if any, each poses to established pharmaceutical companies on a global scale.

Read the full article here http://www.researchpartnership.com/news/2015/07/competition-from-within/

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Research Partnership has been ranked in the Pharma Times Pharma Fast 50

Industry Magazine Pharma Times has partnered with Catalyst Corporate Finance to publish a detailed analysis of the 50 fastest growing private, independently owned pharma companies in the UK and Research...

Women’s health in emerging markets

Why can understanding and improving women’s health in emerging markets be challenging? What strategies can global pharma develop to support women and overcome these challenges? Associate Director Rachel Howard and...

Research Partnership has published a new Living with Lupus (SLE) market report for 2017

SLE is a progressive and debilitating disease which affects 5 million people worldwide.

PEGASUS AND UCL JOIN FORCES IN INSPIRING HEALTHY DECISIONS

Pegasus, an Ashfield company, part of UDG Healthcare plc, is proud to announce the launch of its new propriety model for planning in health – CHANGE – which was developed...

Cool heads in a crisis?

Understanding the role pharmaceutical companies can play in fighting today’s global health pandemics

Biosimilars: Bringing patients into the conversation

Published in eyeforpharma January 2017 by Mariel Metcalfe

Access and elimination: the future of DAAs in hepatitis C

Published in Pharmaphorum January 2017

EphMRA One Day Meeting

We are delighted to be attending and presenting a paper at the EphMRA one day meeting on Tuesday 21st February, in London

Video: Segmentation research

Why would a pharma company want to carry out a segmentation study? What are some of the challenges? Head of Business Analytics Tom Nolte and Associate Director Dr Marianne Jaeger...

Pharmaceutical Market Research Conference 2017

We are delighted to be exhibiting and presenting a paper at the Pharmaceutical Market Research Conference 1-2 February in Parsippany, NJ.